Cardiovascular and Autonomic Responses after a Single Bout of Resistance Exercise in Men with Untreated Stage 2 Hypertension
Table 2
Spectral analysis of the heart rate variability before and after RE and CTR trial.
Baseline
20 min
80 min
24 h
Heart rate (bpm)
Control trial
62 ± 2
58 ± 2
58 ± 2
67 ± 1
Resistance exercise
64 ± 2
82 ± 2†
71 ± 1†
66 ± 1
Total power (ms2)
Control trial
3210.95 ± 2559.83
3943.32 ± 2312.90
4655.87 ± 2940.15
1885.68 ± 1095.88
Resistance exercise
3050.01 ± 2082.16
772.59 ± 765.27†
2044.91 ± 1305.78†
2042.24 ± 967.75
LF (ms2)
Control trial
1213.68 ± 910.16
1711.86 ± 1665.67
1968.06 ± 2397.95
863.02 ± 585.61
Resistance exercise
1240.59 ± 760.96
314.76 ± 367.01†
532.79 ± 248.99†
874.38 ± 429.65
HF (ms2)
Control trial
588.08 ± 428.68
635.88 ± 470.38
940.03 ± 711.08
312.36 ± 292.73
Resistance exercise
520.36 ± 332.92
147.19 ± 166.96†
547.73 ± 1004.91
349.30 ± 242.97
LFn (n.u)
Control trial
69.31 ± 10.45
69.35 ± 10.65
63.36 ± 14.59
70.03 ± 16.43
Resistance exercise
65.90 ± 14.08
61.31 ± 17.05
61.66 ± 25.19
70.53 ± 10.69
HFn (n.u)
Control trial
28.63 ± 10.00
28.88 ± 10.13
34.47 ± 14.47
25.91 ± 13.77
Resistance exercise
29.68 ± 11.38
31.14 ± 11.38
32.30 ± 18.91
26.15 ± 9.72
SDNN (ms)
Control trial
62.9 ± 24
65.3 ± 35
74.5 ± 28
44.1 ± 29
Resistance exercise
61.9 ± 19
32.8 ± 24†
47.8 ± 16†
46.3 ± 23
PNN50
Control trial
17.4 ± 5.7
21.8 ± 5.9
25.4 ± 8.7
7.5 ± 4.0
Resistance exercise
16.2 ± 5.8
3.6 ± 2.6†
9.5 ± 4.3†
10.1 ± 4.7
RMSSD (ms)
Control trial
42.4 ± 18.4
46.8 ± 21.1
51.7 ± 19.7
28.0 ± 11.2
Resistance exercise
44.2 ± 19.0
19.3 ± 9.8†
31.3 ± 12.3†
30.6 ± 16.7
LF, low-frequency power; HF, high-frequency power; n.u. normalized units; SDNN, standard deviation of normal-to-normal; PNN50, proportion of differences in successive NN intervals >50 ms; RMSSD, square root of the mean squared successive differences in pulse interval. versus baseline; †versus same moment of CTR trial.
